These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 19052452)

  • 1. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
    Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.
    Papaliagkas VT; Anogianakis G; Tsolaki MN; Koliakos G; Kimiskidis VK
    Dement Geriatr Cogn Disord; 2009; 28(1):30-5. PubMed ID: 19628938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
    Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ
    Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
    Bjerke M; Andreasson U; Rolstad S; Nordlund A; Lind K; Zetterberg H; Edman A; Blennow K; Wallin A
    Dement Geriatr Cogn Disord; 2009; 28(4):348-56. PubMed ID: 19864909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
    Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
    Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No correlation between time-linked plasma and CSF Abeta levels.
    Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
    Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
    Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
    Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
    Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.